1-20 of 23
Annette Lam
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Post-Hoc Analysis of Efficacy and Safety in the SWOG S0777 Trial Stratified By Age

Brian G.M. Durie, Annette Lam, Mai Ngo, Huiling Pei, Eric M. Ammann
Journal: Blood
Blood (2022) 140 (Supplement 1): 10009–10010.
https://doi.org/10.1182/blood-2022-165591
Published: 2022
Journal Articles

Indirect Treatment Comparisons of Daratumumab, Pomalidomide, and Dexamethasone Versus Daratumumab, Bortezomib, and Dexamethasone or Bortezomib and Dexamethasone in Patients with Difficult-to-Treat Relapsed/Refractory Multiple Myeloma

Jianming He, Heather Berringer, Bart Heeg, Tobias Kampfenkel, Harikumaran R. Dwarakanathan, Stephen Johnston, João Mendes, Annette Lam, Sacheeta Bathija, Eric Mackay
Journal: Blood
Blood (2021) 138 (Supplement 1): 4083.
https://doi.org/10.1182/blood-2021-146044
Published: 2021
Journal Articles

First-Line Use of Daratumumab, Lenalidomide, and Dexamethasone Confers Survival Benefit Compared with Second-Line Use of Daratumumab-Based Regimens in Transplant-Ineligible Patients with Multiple Myeloma: Analysis of Different Clinical Scenarios

Rafael Fonseca, Thierry Facon, Mahmoud Hashim, Sandhya Nair, Jianming He, Eric M. Ammann, Annette Lam, Mark Wildgust, Shaji Kumar
Journal: Blood
Blood (2021) 138 (Supplement 1): 118.
https://doi.org/10.1182/blood-2021-144914
Published: 2021
Journal Articles

Real-World Treatment Patterns in Patients with Light Chain (AL) Amyloidosis: Analysis of the Optum US Electronic Health Records and Commercial Claims Database

Angela Dispenzieri, MD, Jeff Zonder, MD, James Hoffman, MD, Sandy W. Wong, MD, Michaela Liedtke, MD, Rafat Abonour, MD, Anita D'Souza, MBBS, Charlene Lee, MSc, Sandhya Nair, PhD MSc, Ravi Potluri, PGDM, Brendan M. Weiss, MD, Jessica Vermeulen, MD PhD, Annette Lam, MSc, Maneesha Mehra, MPH
Journal: Blood
Blood (2020) 136 (Supplement 1): 4–5.
https://doi.org/10.1182/blood-2020-140405
Published: 2020
Journal Articles

Interim Results of a Time and Motion Survey Regarding Subcutaneous Versus Intravenous Administration of Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma

Mary Slavcev, Allison Spinelli, MSc, Elisabeth Absalon, Tara Masterson, MSc, Chris Heuck, MD, Annette Lam, MSc, Erwin De Cock, MSc
Journal: Blood
Blood (2020) 136 (Supplement 1): 30–31.
https://doi.org/10.1182/blood-2020-139995
Published: 2020
Journal Articles

Real-World Use of Maintenance Therapy and Associated Outcomes Following Autologous Stem Cell Transplant in US Patients with Newly Diagnosed Multiple Myeloma

Eric M. Ammann, PhD, Annette Lam, MSc, Wenze Tang, MPH, Tobias Kampfenkel, MD, Mohit Sharma, Charlene Lee, MSc, Shuchita Kaila, PhD, Alex Z. Fu, PhD, Kathleen Gray, PhD, Jianming He, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 25–26.
https://doi.org/10.1182/blood-2020-139882
Published: 2020
Journal Articles

Effectiveness of Daratumumab in Combination with Lenalidomide and Dexamethasone (DRd) Vs. Common Standard-of-Care Regimens in Patients with Non-Transplant Newly Diagnosed Multiple Myeloma (NDMM)

Brian G.M. Durie, MD, Shaji K. Kumar, MD, Saad Z. Usmani, MD, Bareng A.S. Nonyane, Eric A. Ammann, Annette Lam, Rachel Kobos, MD, Eric M Maiese, PhD, Thierry Facon, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1830.
https://doi.org/10.1182/blood-2019-122937
Published: 2019
Journal Articles

Comparison of Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) with Standard of Care for Patients from Latin America with Newly Diagnosed Multiple Myeloma (NDMM) Who Were Transplant Ineligible: A Propensity Score Matching Analysis

Vania T.M. Hungria, MD PhD, Deborah M. Martinez-Banos, Maria-Victoria Mateos, Meletios A. Dimopoulos, MD, Michele Cavo, Bart Heeg, PhD, Annette Lam, Gerardo Machnicki, Jianming He, PhD, Mariana Fernandez
Journal: Blood
Blood (2019) 134 (Supplement_1): 2143.
https://doi.org/10.1182/blood-2019-123557
Published: 2019
Journal Articles

A Network Meta-Analysis (NMA) to Evaluate Comparative Effectiveness of Frontline Treatments for Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Transplant-Ineligible (TIE)

Thierry Facon, MD, Jesús San-Miguel, Saad Z. Usmani, MD, Meletios A. Dimopoulos, MD, Shaji K. Kumar, MD, Maria-Victoria Mateos, Michele Cavo, Bart Heeg, PhD, Sophie Van Beekhuizen, MSc, Marta Pisini, MBA, Sandhya Nair, Annette Lam, BSc, MSc, Mary Slavcev, Jianming He, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2144.
https://doi.org/10.1182/blood-2019-123561
Published: 2019
Journal Articles

Comparative Efficacy and Safety of Bortezomib, Thalidomide, and Dexamethasone (VTd) without and with Daratumumab (D-VTd) from Cassiopeia Versus Vtd from Pethema/GEM in Patients with Newly Diagnosed Multiple Myeloma Using Propensity Score Matching (PSM)

Philippe Moreau, MD, Cyrille Hulin, MD, Sonja Zweegman, MD PhD, Yannan Hu, PhD, Bart Heeg, PhD, Mahmoud Hashim, Carla de Boer, Veronique Vanquickelberghe, Tobias Kampfenkel, MD, Annette Lam, Sarah Cote, Pieter Sonneveld
Journal: Blood
Blood (2019) 134 (Supplement_1): 4740.
https://doi.org/10.1182/blood-2019-123491
Published: 2019
Journal Articles

Expanded Meta-Analyses Confirms the Association between MRD and Long-Term Survival Outcomes in Multiple Myeloma (MM)

Nikhil C. Munshi, MD, Herve Avet-Loiseau, MD PhD, Kenneth C. Anderson, MD, Paola Neri, MD PhD, Bruno Paiva, PhD, Mehmet Samur, PhD, Meletios A. Dimopoulos, MD, Margarita Kulakova, Bart Heeg, PhD, Mahmoud Hashim, Jon Ukropec, PhD, Kevin Liu, Maria Krevvata, PhD, Annette Lam, Sarah Cote, Nizar Bahlis, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4742.
https://doi.org/10.1182/blood-2019-124191
Published: 2019
Journal Articles

The Relationship between Minimal Residual Disease and Patient Reported Outcomes in Relapsed/Refractory Multiple Myeloma

Hervé Avet-Loiseau, MD PhD, Jianming He, PhD, Katharine S. Gries, PhD PharmD, Huiling Pei, PhD, Sourish Saha, Christopher Chiu, PhD, Sarah Cote, Annette Lam
Journal: Blood
Blood (2018) 132 (Supplement 1): 3273.
https://doi.org/10.1182/blood-2018-99-113571
Published: 2018
Journal Articles

Comparative Efficacy and Safety of Daratumumab in Combination with Bortezomib, Melphalan, and Prednisone (D-VMP) in Alcyone Versus Bortezomib, Melphalan, and Prednisone (VMP) in Vista in Newly Diagnosed Multiple Myeloma (NDMM) Patients Using Propensity Score Matching (PSM)

Michele Cavo, MD, Meletios A Dimopoulos, MD, Jesus F San-Miguel, MD PhD, Maria-Victoria Mateos, MD PhD, Andrzej Jakubowiak, MD PhD, William Deraedt, Annette Lam, Tobias Kampfenkel, MD, Ming Qi, MD PhD, Jianming He, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3550.
https://doi.org/10.1182/blood-2018-99-113128
Published: 2018
Journal Articles

Characterization of Frontline Treatment Patterns and Attrition Rates According to Subsequent Lines of Therapy in Non-Transplant Patients with Newly Diagnosed Multiple Myeloma

Rafael Fonseca, MD, Saad Z. Usmani, MD, Maneesha Mehra, Mary Slavcev, Jon Ukropec, PhD, Annette Lam, Ravi Potluri
Journal: Blood
Blood (2018) 132 (Supplement 1): 3291.
https://doi.org/10.1182/blood-2018-99-113125
Published: 2018
Journal Articles

A Matching-Adjusted Indirect Treatment Comparison of Daratumumab-Bortezomib-Melphalan-Prednisone Versus Lenalidomide-Dexamethasone Continuous, Lenalidomide-Dexamethasone 18 Months, and Melphalan-Prednisone-Thalidomide

Meletios A Dimopoulos, MD, Michele Cavo, MD, Maria-Victoria Mateos, MD PhD, Thierry Facon, Bart Heeg, PhD, Sophie van Beekhuizen, Sandhya Nair, Marta Pisini, MBA, Annette Lam, Mary Slavcev
Journal: Blood
Blood (2018) 132 (Supplement 1): 3551.
https://doi.org/10.1182/blood-2018-99-113517
Published: 2018
Journal Articles

Impact of Modified Dose Schedule of Bortezomib, Melphalan, and Prednisone (VMP) for Previously Untreated, Transplant-Ineligible Patients with Multiple Myeloma (MM): A Matching-Adjusted Indirect Comparison

Jesus F San-Miguel, MD PhD, Maria-Victoria Mateos, MD PhD, Hartmut Goldschmidt, MD, Pieter Sonneveld, MD PhD, Meletios A Dimopoulos, MD, Bart Heeg, PhD, Mahmoud Hashim, William Deraedt, Peter Hu, Annette Lam, Jianming He, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3553.
https://doi.org/10.1182/blood-2018-99-113157
Published: 2018
Journal Articles

Evaluation and Comparison of Characteristics and Outcomes Among Frontline Multiple Myeloma (FLMM) Patients with and without Stem Cell Transplant Treatment

Ajai Chari, MD, Maneesha Mehra, Mary Slavcev, Annette Lam, Ravi Potluri, Jonathan L Kaufman, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4738.
https://doi.org/10.1182/blood-2018-99-113176
Published: 2018
Journal Articles

Treatment Regimens for Patients with Newly Diagnosed Multiple Myeloma Who Are Ineligible for Stem Cell Transplantation: A Systematic Literature Review and Network Meta-Analysis

Jesus F San-Miguel, MD PhD, Thierry Facon, Meletios A Dimopoulos, MD, Maria-Victoria Mateos, MD PhD, Michele Cavo, MD, Bart Heeg, PhD, Sophie van Beekhuizen, Marta Pisini, MBA, Sandhya Nair, Annette Lam, Mary Slavcev
Journal: Blood
Blood (2018) 132 (Supplement 1): 4741.
https://doi.org/10.1182/blood-2018-99-113668
Published: 2018
Journal Articles

Evaluation of Efficacy Outcomes Among Relapsed/Refractory Multiple Myeloma Treated Patients in a Real-World Setting

Ajay Nooka, MDMPH, Peter M. Voorhees, MD, Shaji K Kumar, MD, Maneesha Mehra, Annette Lam, Mary Slavcev, Jon Ukropec, Ravi Potluri, Anandaroop Dasgupta
Journal: Blood
Blood (2017) 130 (Supplement 1): 3093.
https://doi.org/10.1182/blood.V130.Suppl_1.3093.3093
Published: 2017
Journal Articles

Comparison of Overall Survival Associated with Lenalidomide+Dexamethasone and Bortezomib+Dexamethasone Among Relapsed/Refractory Multiple Myeloma Patients: A Matched Analysis of Real World and Clinical Trial Populations

Ajay Nooka, MDMPH, Peter M. Voorhees, MD, Shaji K Kumar, MD, Maneesha Mehra, Annette Lam, Mary Slavcev, Ravi Potluri, Anandaroop Dasgupta
Journal: Blood
Blood (2017) 130 (Supplement 1): 3094.
https://doi.org/10.1182/blood.V130.Suppl_1.3094.3094
Published: 2017